GAAP revenue dropped to zero in Q2 2025, with no new product sales or clinical trial sponsorships. Net loss per share (GAAP) was $(0.42) in Q2 2025, reflecting significant spending cuts and a ...

Eternal shares slipped on Thursday after a Rs 5,624 crore block deal took place on the bourses, with Antfin likely fully ...